ArticleSurgical endoscopy2025
Prospective validation and revision of predictive models for post-ERCP pancreatitis: focus on procedure-related factors and a novel risk stratification approach.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Early risk stratification of post-endoscopic retrograde cholangiopancreatography pancreatitis using 4-hour serum amylase and lipase: A prospective study.World journal of gastroenterology · 2025Article
- Enucleation of Pancreatic Lesions: The Outcomes and Experiences from Two Centers.Annals of surgical oncology · 2025Article
- Predictive models for post-ERCP pancreatitis: a systematic review and meta-analysis.Frontiers in gastroenterology (Lausanne, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionPost-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most common serious adverse event after endoscopic retrograde cholangiopancreatography (ERCP). Although retrospective models to predict PEP have shown promise, their real-world applicability remains uncertain. Thus, we used prospectively derived cohort data to validate current prediction models.
methodsWe conducted a prospective cohort study involving patients who underwent ERCP between August 2020 and December 2023. We validated the original PEP-risk prediction models using prospective cohort data and, if necessary, refined them using logistic regression analysis.
resultsAmong the 1112 study participants, the original PEP-risk prediction models had limited performance. Although PEP incidence tended to increase across risk groups, the differences were mostly insignificant. Logistic regression highlighted procedural factors-total procedure time [odds ratio (OR) 1.13, 95% confidence interval (CI) 1.01-1.26 per 5 min], unintended pancreatic duct cannulation (OR 2.56, 95% CI 1.11-5.93), and pancreatic opacification (OR 2.57, 95% CI 1.19-5.58)-as independent PEP risk factors. This led to a revised model that assigned 1, 8, and 8 points to these factors. Patients stratified into low- (0-2 points), intermediate- (3-10 points), and high-risk groups (≥ 11 points) exhibited PEP incidences of 2.6% (95% CI 1.5-4.1%), 7.1% (95% CI 4.8-10.3%), and 12.6% (95% CI 8.6-17.8%), respectively.
conclusionsWe highlighted limitations of existing PEP-prediction models that necessitate refinement based on procedural variables. Our revised model accounted for the prolonged total procedure time, unintended pancreatic duct cannulation, and pancreatic opacification, offering enhanced accuracy in predicting PEP risk.
Indexed as
Identifiers
39738907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.